S 
Shanghai MicroPort Endovascular MedTech Group Co 688016.SS · CNY
Health Care · Shanghai · 🇨🇳 China
86.72
-1.21%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥1.35bn
FY2016FY2025
Net income
CN¥563.2m
FY2016FY2025
Free cash flow
CN¥270.0m
FY2016FY2025
Shareholders' equity
CN¥3.98bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.35bn | CN¥1.21bn | CN¥1.19bn | CN¥896.5m | CN¥684.6m | CN¥470.3m | CN¥333.7m | CN¥231.1m | CN¥165.1m | CN¥125.3m |
| Research and development | CN¥67.8m | CN¥93.8m | CN¥172.9m | CN¥137.5m | CN¥102.3m | CN¥73.0m | CN¥49.6m | CN¥29.7m | CN¥20.1m | CN¥20.1m |
| Operating income | CN¥653.9m | CN¥661.2m | CN¥573.9m | CN¥415.2m | CN¥362.8m | CN¥249.9m | CN¥164.3m | CN¥104.8m | CN¥73.9m | CN¥45.4m |
| Net income | CN¥563.2m | CN¥502.1m | CN¥492.4m | CN¥356.9m | CN¥315.9m | CN¥214.6m | CN¥141.8m | CN¥90.6m | CN¥63.4m | CN¥41.1m |
| Diluted earnings per share | 4.66 | 4.06 | 4.52 | 3.33 | 2.96 | 1.99 | 1.33 | 1.13 | 0.52 | 0.34 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥4.64bn | CN¥4.29bn | CN¥4.25bn | CN¥2.00bn | CN¥1.75bn | CN¥1.38bn | CN¥1.16bn | CN¥268.8m | CN¥224.3m | CN¥188.6m |
| Cash and short-term investments | CN¥2.14bn | CN¥2.17bn | CN¥2.97bn | CN¥976.9m | CN¥1.24bn | CN¥1.05bn | CN¥889.2m | CN¥49.9m | CN¥31.8m | CN¥27.7m |
| Total liabilities | −CN¥3.98bn | CN¥469.1m | CN¥382.6m | CN¥252.5m | CN¥231.5m | CN¥142.1m | CN¥89.7m | CN¥52.7m | CN¥36.2m | CN¥65.2m |
| Debt | — | CN¥28.0m | CN¥35.7m | CN¥41.2m | CN¥45.8m | CN¥18.5m | CN¥3.6m | CN¥1.3m | CN¥943,269 | CN¥713,218 |
| Shareholders' equity | CN¥3.98bn | CN¥3.79bn | CN¥3.84bn | CN¥1.72bn | CN¥1.49bn | CN¥1.23bn | CN¥1.07bn | CN¥216.2m | CN¥188.0m | CN¥123.4m |
| Shares outstanding | 121m | 124m | 109m | 107m | 107m | 108m | 106m | 80m | 121m | 121m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥573.1m | CN¥373.6m | CN¥571.2m | CN¥333.8m | CN¥300.3m | CN¥217.4m | CN¥143.2m | CN¥106.9m | CN¥69.4m | CN¥30.1m |
| Capital spending | −CN¥303.0m | −CN¥212.6m | −CN¥190.3m | −CN¥294.0m | −CN¥89.6m | −CN¥26.2m | −CN¥21.2m | −CN¥24.9m | −CN¥28.2m | −CN¥31.8m |
| Free cash flow | CN¥270.0m | CN¥161.0m | CN¥381.0m | CN¥39.8m | CN¥210.7m | CN¥191.2m | CN¥122.0m | CN¥81.9m | CN¥41.1m | −CN¥1.7m |
| Dividends paid | −CN¥201.8m | −CN¥450.5m | −CN¥165.5m | −CN¥151.2m | −CN¥64.8m | −CN¥46.8m | −CN¥22.5m | −CN¥64.0m | −CN¥37.4m | −CN¥7.4m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥423.7m | CN¥370.2m | CN¥335.9m | CN¥300.4m | CN¥382.2m | CN¥332.2m | CN¥236.8m | CN¥182.4m |
| Operating income | CN¥202.5m | CN¥184.6m | CN¥156.4m | CN¥130.4m | CN¥216.2m | CN¥150.9m | CN¥23.4m | CN¥165.0m |
| Net income | CN¥167.5m | CN¥154.8m | CN¥134.2m | CN¥114.4m | CN¥185.0m | CN¥129.6m | −CN¥51.2m | CN¥149.8m |
| Diluted earnings per share | 1.39 | 1.28 | 1.11 | 0.95 | 1.53 | 1.07 | -0.41 | 1.21 |
| Cash from operations | — | — | — | CN¥46.0m | CN¥278.0m | CN¥40.0m | — | CN¥36.0m |
| Capital spending | −CN¥50.0m | −CN¥29.0m | −CN¥88.0m | −CN¥86.0m | −CN¥28.0m | −CN¥100.0m | −CN¥89.0m | −CN¥43.0m |
| Free cash flow | — | — | — | −CN¥40.0m | CN¥250.0m | −CN¥60.0m | — | −CN¥7.0m |
| Total assets | CN¥4.96bn | CN¥4.79bn | CN¥4.64bn | CN¥4.73bn | CN¥4.60bn | CN¥4.46bn | CN¥4.29bn | CN¥4.56bn |
| Cash and short-term investments | — | — | CN¥2.14bn | CN¥2.14bn | CN¥2.22bn | CN¥2.15bn | CN¥2.17bn | CN¥2.50bn |
| Debt | — | — | — | CN¥11.7m | — | CN¥140.0m | CN¥14.0m | — |
| Shareholders' equity | CN¥4.26bn | CN¥4.22bn | CN¥3.98bn | CN¥3.96bn | CN¥4.03bn | CN¥3.85bn | CN¥3.79bn | CN¥3.89bn |
Financial ratios
Data as of 2 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 48.4% | 54.8% | 48.3% | 46.3% | 53.0% | 53.1% | — |
| Net margin | 41.7% | 41.6% | 41.5% | 39.8% | 46.1% | 45.6% | — |
| Return on equity | 14.1% | 13.2% | 12.8% | 20.8% | 21.1% | 17.4% | — |
| Return on assets | 12.1% | 11.7% | 11.6% | 17.9% | 18.0% | 15.6% | — |
| Free cash flow yield | 8.5% | 5.5% | 8.2% | 6.9% | 4.3% | 2.6% | — |
| Revenue growth | 12.0% | 1.6% | 32.4% | 30.9% | 45.6% | 40.9% | — |
| Earnings growth | 12.2% | 2.0% | 38.0% | 13.0% | 47.2% | 51.4% | — |
| Current ratio | 6.85x | 8.08x | 10.76x | 6.93x | 9.00x | 10.44x | — |
| Debt to equity | — | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x |
| Equity ratio | 85.8% | 88.4% | 90.5% | 86.1% | 85.2% | 89.7% | — |
| Interest coverage | 302.65x | 325.20x | 281.23x | 178.08x | 187.89x | 2174.16x | — |
| R&D as a share of sales | 5.0% | 7.8% | 14.6% | 15.3% | 14.9% | 15.5% | — |
| Buybacks as a share of market value | 2.3% | -13.5% | -1.9% | -0.3% | 1.1% | -1.5% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 14.6% | 23.5% | — |
| Operating income | 16.3% | 21.2% | — |
| Net income | 16.4% | 21.3% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Price to earnings | 19.7 | 27.1 | 28.9 | 38.1 | 56.4 | 84.8 | 74.1 |
| Price to sales | 8.2 | 11.3 | 12.0 | 15.2 | 26.0 | 38.7 | 31.5 |
Dividends and splits
Per share, in the currency the company pays
Paid for 6 years. Last went ex-dividend on 5 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Paid in the year | 1.00 | 1.65 | 3.675 | 1.544 | 1.409 | 0.604 | 0.436 |
- 1.49-for-1 split · 14 May 2024
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.